$20m wheeze gives MediciNova breathing room for FDA and partnering
This article was originally published in Scrip
MediciNova entered into a common stock purchase agreement with Aspire Capital Fund that gives it access to $20 million over the next two years as the San Diego-based biopharma company prepares to tell the US FDA at a 22 October end-of-Phase II meeting why its acute asthma drug MN-221 (bedoradrine) should be tested in a Phase III clinical trial.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.